Monopar Therapeutics Unveils Promising Phase 2 Study Results

The latest announcement is out from Monopar Therapeutics Inc ( (MNPR) ).

On November 9, 2025, Monopar Therapeutics presented new data from the Phase 2 ALXN1840-WD-204 copper balance study at The Liver Meeting® 2025. The study showed that ALXN1840 (tiomolybdate choline) led to rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion, marking a significant advancement in treatment options for this condition.

The most recent analyst rating on (MNPR) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.

Spark’s Take on MNPR Stock

According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.

Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.

To see Spark’s full report on MNPR stock, click here.

More about Monopar Therapeutics Inc

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. The company is involved in late-stage development of ALXN1840 for Wilson disease and has radiopharmaceutical programs including MNPR-101-Zr for imaging advanced cancers, as well as MNPR-101-Lu and MNPR-101-Ac225 for the treatment of advanced cancers.

Average Trading Volume: 76,979

Technical Sentiment Signal: Buy

Current Market Cap: $583.2M

Learn more about MNPR stock on TipRanks’ Stock Analysis page.